2018 Fiscal Year Final Research Report
Development of a new diagnostic method for heart failure in collaboration with drug engineers
| Project/Area Number |
26242055
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical systems
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
井上 豪 大阪大学, 工学(系)研究科(研究院), 教授 (20263204)
角田 慎一 国立研究開発法人医薬基盤・健康・栄養研究所, その他部局等, その他 (90357533)
|
|---|
| Research Collaborator |
Sakata Yasushi
Fujio Yasushi
Kioka Hidetaka
Nishida Makoto
Obana Masanori
Sawa Yoshiki
Hamakubo Takao
Tsumoto Kohei
Murase Norio
Kamada Haruhiko
Yoshioka Yasuo
Mukai Yohei
Nagano Kazuya
Higashisaka Kazuma
|
|---|
| Project Period (FY) |
2014-04-01 – 2019-03-31
|
| Keywords | 心不全 / バイオマーカー / 検査・診断システム |
|---|
| Outline of Final Research Achievements |
This study aimed to develop biomarker proteins for early diagnosis and pathologic diagnosis for heart failure which has been regarded as a national disease, and the following useful diagnostic method by creating a high-affinity antibody. From this viewpoint, based on our findings obtained by proteomic analysis using the serum before and after the heart, the representative found that cytoskeletal proteins can be a heart failure biomarker in humans. Furthermore, we revealed that this candidate protein might suppress myocardial cell death in an ischemic-like condition. In the future, we will investigate the usefulness of this candidate protein as a heart failure biomarker by assessing the samples of heart failure patient of many cases in comparison with information of patient's disease state history.
|
| Free Research Field |
人間医工学
|
| Academic Significance and Societal Importance of the Research Achievements |
心不全の病態は多様であり、予後を予測するためのバイオマーカーが確立されているわけではない。従って、本研究成果により、心不全病態に対する特異的血清バイオマーカーが確立されれば、侵襲の多い診断を避けた新しい診断技術に基づき、心不全に対する先制医療が可能となる。また、新たな治療ターゲットの探索になる可能性も秘めており、基礎医学、臨床医学の両方の観点からも、医学的に意義深い臨床研究を遂行できる。さらに、心不全の予防や重症化阻止のみならず、心疾患がもたらす医療費削減にもつながるものと期待される。
|
